Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on July 20, 2026 reporting Item 8.01 (Other Events). Positive 2-year PRISM Phase 2b data support 4D-150 durability in broad wet AMD.
4D Molecular Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Positive 2-year PRISM Phase 2b data support 4D-150 durability in broad wet AMD
- Treatment burden reduced 78% overall, with 2.7 supplemental injections versus 12.0 projected for aflibercept
- Recently diagnosed subgroup achieved 87% burden reduction, with 1.6 supplemental injections versus 12.0 projected
- Phase 3 dose maintained efficacy response; 3E10 vg/eye selected for 4FRONT Phase 3 trials
- Safety profile favorable: 2.8% mild inflammation and no new cases after 28 weeks; no reported hypotony or endophthalmitis
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 4D Molecular Therapeutics, Inc. 8-K filings
Get the next FDMT 8-K as it lands
Follow FDMT for push alerts, or ask the research agent what this filing means.